- Home
- GYRE vs NVGS Comparison
GYRE vs NVGS Comparison
Compare GYRE & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NVGS
- Stock Information
- Founded
- GYRE 2002
- NVGS 1997
- Country
- GYRE United States
- NVGS United Kingdom
- Employees
- GYRE N/A
- NVGS N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NVGS Marine Transportation
- Sector
- GYRE Health Care
- NVGS Consumer Discretionary
- Exchange
- GYRE Nasdaq
- NVGS Nasdaq
- Market Cap
- GYRE 1.1B
- NVGS 1.1B
- IPO Year
- GYRE N/A
- NVGS N/A
- Fundamental
- Price
- GYRE $12.02
- NVGS $17.03
- Analyst Decision
- GYRE
- NVGS Strong Buy
- Analyst Count
- GYRE 0
- NVGS 3
- Target Price
- GYRE N/A
- NVGS $22.00
- AVG Volume (30 Days)
- GYRE 91.0K
- NVGS 218.6K
- Earning Date
- GYRE 03-25-2025
- NVGS 03-12-2025
- Dividend Yield
- GYRE N/A
- NVGS 1.18%
- EPS Growth
- GYRE N/A
- NVGS 13.48
- EPS
- GYRE N/A
- NVGS 1.12
- Revenue
- GYRE $105,033,000.00
- NVGS $564,280,000.00
- Revenue This Year
- GYRE $25.32
- NVGS $0.05
- Revenue Next Year
- GYRE $12.95
- NVGS $4.76
- P/E Ratio
- GYRE N/A
- NVGS $14.81
- Revenue Growth
- GYRE N/A
- NVGS 5.99
- 52 Week Low
- GYRE $8.26
- NVGS $14.55
- 52 Week High
- GYRE $26.37
- NVGS $18.18
- Technical
- Relative Strength Index (RSI)
- GYRE 54.44
- NVGS 61.23
- Support Level
- GYRE $11.18
- NVGS $16.14
- Resistance Level
- GYRE $11.85
- NVGS $17.23
- Average True Range (ATR)
- GYRE 0.52
- NVGS 0.47
- MACD
- GYRE 0.14
- NVGS 0.01
- Stochastic Oscillator
- GYRE 83.91
- NVGS 69.38
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).